Checkpoint is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in an ongoing global, ...

3D rendering of a checkpoint inhibitor binding PD-1, a protein on the surface of an immune T cell. This article is part of an ongoing series on checkpoint inhibitors, a novel cancer immunotherapy.

WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial ...

Skin cancers, lung cancers, lymphomas—though these cancers affect different parts of the body, they can all be treated with one of the latest therapies medicine has to offer: checkpoint inhibitors.